Clinical Trial With N-acetylcysteine and Bromhexine for COVID-19

Launched by UNIVERSIDADE FEDERAL DO CEARA · Jun 15, 2021

Keywords

ClinConnect Summary

Several therapeutic agents have been evaluated for the treatment of COVID-19, but only one, the antiviral drug called remdesivir administered intravenously, has shown to be effective in shortening the duration of the disease by 26.7% in critically ill patients. This proposal has the primary objective (1) to determine the effect of N-acetylcysteine (NAC; reducing substance and complementary viral intercepting action) and combination of NAC + bromhexine (BMX; viral protease inhibitor), on the clinical duration of COVID-19 evaluated on the 7th. day of outpatient follow-up, observing the score ...

Gender

ALL

Eligibility criteria

• The inclusion criteria will be:
• • 1. patients with clinical signs and symptoms of COVID-19; and
• • 2. patients over 18 years and below 60 years of age.
• The exclusion criteria will be:
• • 1. participate in another clinical intervention study;
• • 2. you have a disease or other medical condition that prevents you from using the medications for this intervention;
• • 3. patient incapable of ingesting, retaining and absorbing the intervention medications; and (d) is mentally disabled.